Stocks · News reference
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $270 to $271.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Jazz Pharmaceuticals plc (JAZZ)
Filed: 2026-09-23 AccNo: 0001193125-26-399425 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development
Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the Qatar Investment Authority, filed to go public Monday.
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
Jazz Pharmaceuticals acquired Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments to gain control of ABS-1230, a potential first-in-class treatment for KCNT1-related epilepsy. The acquisition strengthens Jazz's existing epilepsy franchise, which includes the successful Epidiolex drug generating $292 million in Q2 sales. While clinical trial risks exist, Jazz's strong revenue growth (16% YoY to $1.2 billion in Q2) and solid cash generation support the investment. At 9.5x forward earnings, the stock appears reasonably valued for a profitable biotech with double-digit growth.